How AMT-143 could reduce the post-surgical need for opioids

   Press Release

In June 2022, we created and published Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation.

Watch the AMT-143 animation below:

The short video explains how AMT-143, our first formulation, addresses the critical 72-hour postoperative period when patients report the highest pain levels. When approved, it may help to reduce patients’ risk of opioid dependency while increasing relief.

About AmacaThera

AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Learn more about our technology.

More Recent News

AmacaThera featured in Innovate Toronto

   Media Coverage

AmacaThera’s drug development platform is featured in Innovate Toronto, an in-depth look at Toronto’s innovation ecosystem. The online compendium and coffee table book features over 300 start-up success stories, including Kepler, which aims to take the Internet into space, and Altus Assessments, which is using data and tech to bring the human side of healthcare education back into focus.
Read more

AmacaThera animation showcases company’s unique biotechnology

   Press Release

In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a one-minute animation that outlines its approach to drug development.Read more

AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute

   Press Release

adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

661 University Ave, Suite 1300
Toronto, ON M5G 0B7, Canada

info@amacathera.ca